An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder

Trial Profile

An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Vibegron (Primary) ; Tolterodine
  • Indications Overactive bladder
  • Focus Registrational; Therapeutic Use
  • Acronyms EMPOWUR
  • Sponsors Urovant Sciences
  • Most Recent Events

    • 28 Mar 2018 Status changed from planning to recruiting, according to an Urovant Sciences media release.
    • 18 Sep 2017 According to an Urovant Sciences media release, the company plans to initiate this confirmatory phase III trial by early 2018.
    • 19 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top